Kinetics of C-Reactive Protein During the Management of Acute Coronary

Status Recruiting

Clinical Trial Summary

The primary objective of the study focuses on the kinetics of plasma CRP measured during the overall management (before the angioplasty procedure until the discharge of hospitalization) of patients with ST+ ACS requiring emergency transluminal angioplasty.

Clinical Trial Description

During the management of acute coronary syndrome with ST segment elevation (ACS-ST+), an ischemia-reperfusion syndrome is observed in connection with primary coronary occlusion (ischemia) and percutaneous angioplasty during the therapeutic coronary reperfusion. This ischemia-reperfusion syndrome results biologically in an inflammatory syndrome evaluated in particular by the assay of C-reactive protein (CRP). CRP is a marker of inflammation used in routine practice. Previous studies have reported the prognostic value of CRP at the 48th hour of hospital treatment for ST+ ACS. If the value of CRP is correlated with the risk of mortality and heart failure, the fact remains that no study has, to date, studied its kinetics during the overall management (pre and intra-hospital) of ACS ST+. This is all the more important since the previous therapies taken by the patient (statins for example) and/or those administered during treatment (colchicine, ticagrelor, anti-GPIIbIIIa are capable of modifying the pre-hospital value of the CRP. In this study, the kinetics of plasma CRP measured during the first medical contact (emergency, cardiology or resuscitation), then, in the catheterization room before the angioplasty procedure, then in the catheterization room, after the angioplasty, then at the 6th hour (H6), at the 12th hour (H12), at the 24th hour (H24), at the 48th hour (H48) and once a week until the 7th day then once a week until discharge hospitalization with a maximum of 30 days of follow-up, as part of the usual follow-up of patients with ST+ ACS requiring emergency transluminal angioplasty. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05233176
Study type	Observational
Source	Assistance Publique - Hôpitaux de Paris
Contact	Romain Jouffroy, MD, PhD
Phone	+ 33 (0)1 49095601
Email	romain.jouffroy@aphp.fr
Status	Recruiting
Phase
Start date	March 2, 2022
Completion date	April 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05846893` - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease	N/A
Recruiting	`NCT06013813` - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI	N/A
Recruiting	`NCT05412927` - AngelMed Guardian® System PMA Post Approval Study
Completed	`NCT02750579` - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?	N/A
Completed	`NCT04102410` - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients	N/A
Enrolling by invitation	`NCT03342131` - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome	N/A
Recruiting	`NCT01218776` - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation	`NCT04676100` - International CR Registry
Completed	`NCT03590535` - 5th Generation cTnT in ED ACS
Recruiting	`NCT05437900` - INSIGHTFUL-FFR Clinical Trial	Phase 4
Completed	`NCT05551429` - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated	`NCT04316481` - IDE-ALERTS Continued Access Study	N/A
Active, not recruiting	`NCT04475380` - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting	`NCT04852146` - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting	`NCT02892903` - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?	N/A
Completed	`NCT04077229` - Piloting Text Messages to Promote Positive Affect and Physical Activity	N/A
Completed	`NCT02944123` - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)	Phase 3
Not yet recruiting	`NCT02871622` - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM	N/A
Active, not recruiting	`NCT02922140` - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit	N/A
Completed	`NCT02673437` - Rivaroxaban ACS Specialist Cohort Event Monitoring Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Kinetics of C-Reactive Protein During the Management of Acute Coronary Syndrome Treated by Transluminal Angioplasty — CRP KIN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms